<DOC>
	<DOCNO>NCT00633997</DOCNO>
	<brief_summary>This study look skin accumulation vildagliptin two major metabolite , LAY151 LAF237-O-Glucuronide , vildagliptin 50 mg give orally twice day 10 day healthy volunteer patient type 2 diabetes .</brief_summary>
	<brief_title>Assessment Skin-concentration Vildagliptin 50 mg Every 12 Hours 10 Days Healthy Subjects Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<criteria>Healthy volunteer patient type 2 diabetes Nonsmoking , Caucasian African American , male female ( postmenopausal , surgically sterile use doublebarrier method contraception ) subject 30 65 year age ( inclusive ) Type 2 diabetic metformin and/or sufonylurea History type 1 diabetes insulin use History coagulation abnormality History abnormal heart condition Pregnancy breastfeed Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Diabetes mellitus</keyword>
	<keyword>type 2 diabetes</keyword>
	<keyword>vildagliptin</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>